AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21312264 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg once daily
Number of subjects: 285
Study 21312264 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 285
Study 21312264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 19779611 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Counselling
Number of subjects: 0
Study 19779611 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (brief intervention)
Number of subjects: 0
Study 16512551 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo-based inverse model for diffuse reflectance
Number of subjects: 41
Study 16512551 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine classification algorithm
Number of subjects: 41
Study 12763981 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction in inhaled corticosteroid dose (stepdown)
Number of subjects: 259
Study 12763981 — intervention group
Group type: COMPARATOR
Intervention: No alteration to inhaled corticosteroid dose (control)
Number of subjects: 259
Study 10678632 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg oral slow-release theophylline (250 mg if <70 kg) taken twice daily
Number of subjects: 35
Study 10678632 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo tablet taken twice daily
Number of subjects: 35
Study 10678632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both theophylline and placebo
Number of subjects: 35
Study 9362433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg) as a 4-hour infusion every 4 weeks for 21 cycles in addition to antimyeloma chemotherapy
Number of subjects: 0
Study 9362433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9362433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 0
Study 8383639 — intervention group
Group type: EXPERIMENTAL
Intervention: Gorging pattern (2 meals daily)
Number of subjects: 14
Study 8383639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nibbling pattern (3 to 5 meals daily)
Number of subjects: 14
Study 8383639 — intervention group
Group type: COMPARATOR
Intervention: Both feeding regimens (Gorging and Nibbling)
Number of subjects: 14
Study 3535005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily) for 6 months
Number of subjects: 31
Study 3535005 — intervention group
Group type: COMPARATOR
Intervention: Fundoplication surgery
Number of subjects: 31
Study 3535005 — intervention group
Group type: COMPARATOR
Intervention: Short-term treatment with ranitidine
Number of subjects: 31
Study 30078745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package including concise information sheet, semi-completed forms, VSS clinic contacts, and text message reminders.
Number of subjects: 833
Study 30078745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 833
Study 30078745 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving publicly available leaflets about VSS
Number of subjects: 833
Study 26812925 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 241
Study 26812925 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 241
Study 26812925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 25316451 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Reappraisal Coping Intervention (PRCI)
Number of subjects: 110
Study 25316451 — intervention group
Group type: COMPARATOR
Intervention: Daily emotional monitoring
Number of subjects: 110
Study 25316451 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 110
Study 22389428 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg/day) plus lifestyle counselling
Number of subjects: 222
Study 22389428 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lifestyle counselling
Number of subjects: 222
Study 20187842 — intervention group
Group type: COMPARATOR
Intervention: DPSGC 50 mg
Number of subjects: 75
Study 20187842 — intervention group
Group type: COMPARATOR
Intervention: DPSGC 25 mg
Number of subjects: 75
Study 20187842 — intervention group
Group type: COMPARATOR
Intervention: DPSGC 25 mg and 50 mg
Number of subjects: 75
Study 18270542 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 99770
Study 18270542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no revaccination)
Number of subjects: 99770
Study 16274480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg prophylactic and 4 mg postoperative IV) and Diclofenac potassium (50 mg oral before and after surgery)
Number of subjects: 100
Study 16274480 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium (50 mg oral before and after surgery)
Number of subjects: 100
Study 11950484 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketanserin given as intravenous boluses every 10 min
Number of subjects: 0
Study 11950484 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketanserin given as intravenous boluses every 20 min
Number of subjects: 0
Study 11950484 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10468799 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol 25 microg/g
Number of subjects: 144
Study 10468799 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol (6, 12.5, 25, and 50 microg/g)
Number of subjects: 144
Study 10468799 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 50 microg/g
Number of subjects: 144
Study 8678261 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.1 mg.kg‐1
Number of subjects: 100
Study 8678261 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.2 mg.kg‐1
Number of subjects: 100
Study 8678261 — intervention group
Group type: EXPERIMENTAL
Intervention: prochlorperazine 0.1 mg.kg‐1
Number of subjects: 100
Study 8678261 — intervention group
Group type: EXPERIMENTAL
Intervention: prochlorperazine 0.2 mg.kg‐1
Number of subjects: 100
Study 8678261 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 100
Study 2149047 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (T) 6 mg/kg/d and Fluconazole (F) 3 mg/kg/d
Number of subjects: 46
Study 2149047 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (T) 10 mg/kg/d, Ceftriaxone (C) 50 mg/kg/d, and Amikacin (A) 15 mg/kg/d
Number of subjects: 46
Study 379841 — intervention group
Group type: EXPERIMENTAL
Intervention: 768 mg chlormethiazole
Number of subjects: 8
Study 379841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30476343 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-based mind-body intervention (n = 26)
Number of subjects: 50
Study 30476343 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 24)
Number of subjects: 50
Study 31597002 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLG
Number of subjects: 1500
Study 28724331 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanites aegyptiaca (BE) capsules (400mg/day) for 8 weeks
Number of subjects: 30
Study 28724331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26669547 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 6 mm-long implants
Number of subjects: 20
Study 26669547 — intervention group
Group type: COMPARATOR
Intervention: 10 mm-long implants
Number of subjects: 20
Study 24424409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg, 3-month loading phase with monthly injections, followed by a 12-month maintenance phase.
Number of subjects: 1729
Study 22940437 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCSS-K6 (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Number of subjects: 128
Study 22940437 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCSS-K3 (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Number of subjects: 128
Study 22940437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lark One cigarettes (1mg tar, 0.1mg nicotine, and 2.0mg CO)
Number of subjects: 128
Study 22940437 — intervention group
Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 128
Study 22940437 — intervention group
Group type: COMPARATOR
Intervention: Marlboro cigarettes (6 mg tar, 0.5mg nicotine, and 7.0mg CO)
Number of subjects: 128
Study 18818045 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal counselling intervention with the GP
Number of subjects: 1260
Study 18818045 — intervention group
Group type: COMPARATOR
Intervention: Control group (week 1)
Number of subjects: 1260
Study 18818045 — intervention group
Group type: COMPARATOR
Intervention: Computer expert system intervention (week 2)
Number of subjects: 1260
Study 17138937 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (350 microg/kg intravenous bolus followed by 25 microg/kg per minute infusion)
Number of subjects: 21
Study 17138937 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg, intravenous bolus)
Number of subjects: 21
Study 17138937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 21
Study 17138937 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 21
Study 15234137 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 11
Study 11318292 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A (CsA)
Number of subjects: 24
Study 11318292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 24
Study 9031498 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT1 alleles with T460C mutation
Number of subjects: 1
Study 9031498 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT1 alleles with G1042A mutation
Number of subjects: 1
Study 9031498 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT1 alleles with both T460C and G1042A mutations
Number of subjects: 1
Study 8293898 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current electrocoagulation
Number of subjects: 50
Study 8293898 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocoagulation
Number of subjects: 50
Study 2965231 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5.1 mg twice daily)
Number of subjects: 17
Study 2965231 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (long-term follow-up)
Number of subjects: 17
Study 30962918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailoring arm (HAPA-based interventions)
Number of subjects: 12
Study 30962918 — intervention group
Group type: COMPARATOR
Intervention: ASH arm (untailored educational sessions)
Number of subjects: 12
Study 29535504 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-019 (130 mg) IV over 30 min
Number of subjects: 97
Study 29535504 — intervention group
Group type: COMPARATOR
Intervention: Fosaprepitant (150 mg) IV over 30 min
Number of subjects: 97
Study 27966411 — intervention group
Group type: EXPERIMENTAL
Intervention: Christmas joy (JN) intervention for three days
Number of subjects: 24
Study 27966411 — intervention group
Group type: COMPARATOR
Intervention: No Christmas joy (JN)
Number of subjects: 24
Study 27966411 — intervention group
Group type: EXPERIMENTAL
Intervention: Christmas joy (JN) intervention
Number of subjects: 24
Study 25065855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg weekly for 5 weeks)
Number of subjects: 19
Study 25065855 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 19
Study 23318239 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-centered dengue-ecosystem management intervention in Demangan and Giwangan neighborhoods
Number of subjects: 6
Study 23318239 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention in Tahunan and Bener neighborhoods
Number of subjects: 6
Study 19231284 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (15 min duration)
Number of subjects: 60
Study 19231284 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (15 min duration)
Number of subjects: 60
Study 17411338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) including protease inhibitor or non-nucleoside reverse transcriptase inhibitor
Number of subjects: 0
Study 17411338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0
Study 16338284 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine gum
Number of subjects: 364
Study 16338284 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 364
Study 12221873 — intervention group
Group type: EXPERIMENTAL
Intervention: Xe:O2 (70:30)
Number of subjects: 44
Study 12221873 — intervention group
Group type: COMPARATOR
Intervention: N2O:O2 (70:30) + phentanyl (0.1 ml boluses every 20 min)
Number of subjects: 44
Study 10076584 — intervention group
Group type: EXPERIMENTAL
Intervention: Food label education program (9 weekly group sessions)
Number of subjects: 43
Study 10076584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 8562295 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice
Number of subjects: 12
Study 2266681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane membrane
Number of subjects: 0
Study 2266681 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate membrane
Number of subjects: 0
Study 7367779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate aerosol (BDA)
Number of subjects: 37
Study 7367779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31294822 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier loads (>60% of maximal strength) during resistance exercise to task failure
Number of subjects: 10
Study 31294822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter loads during resistance exercise to task failure
Number of subjects: 10
Study 27507127 — intervention group
Group type: EXPERIMENTAL
Intervention: Essix retainer
Number of subjects: 30
Study 27507127 — intervention group
Group type: COMPARATOR
Intervention: Hawley retainer
Number of subjects: 30
Study 26190299 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 milliamps for 20 minutes, 5 sessions)
Number of subjects: 37
Study 26190299 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 37
Study 24427796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZCB00 continuous-optic-edge IOL
Number of subjects: 54
Study 24427796 — intervention group
Group type: COMPARATOR
Intervention: Acrysof SA60AT interrupted-optic-edge IOL
Number of subjects: 54
Study 21487425 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component family focused education package (active intervention)
Number of subjects: 65
Study 21487425 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (body composition monitoring alone)
Number of subjects: 65
Study 19782788 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-echocardiographic measures of LV diastolic function (MV E/A, E/E')
Number of subjects: 2331
Study 19782788 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-echocardiographic measures of LV diastolic function (MV E/A)
Number of subjects: 2331
Study 19782788 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-echocardiographic measures of LV diastolic function
Number of subjects: 2331
Study 17255296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy in the metastatic setting
Number of subjects: 0
Study 17255296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant strategies integrating aggressive surgical intervention with systemic therapy
Number of subjects: 0
Study 17255296 — intervention group
Group type: EXPERIMENTAL
Intervention: New targeted therapies
Number of subjects: 0
Study 15119639 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start dialysis (10-14 mL/min/1.73 m2)
Number of subjects: 388
Study 15119639 — intervention group
Group type: COMPARATOR
Intervention: Late start dialysis (5-7 mL/min/1.73 m2)
Number of subjects: 388
Study 11268891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid 500 mg twice a day for 7.5 days
Number of subjects: 313
Study 11268891 — intervention group
Group type: COMPARATOR
Intervention: Pristinamycin 1 g twice a day for 10 days
Number of subjects: 313
Study 9852937 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis initiated by prehospital care providers (physicians or paramedics)
Number of subjects: 0
Study 9852937 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG acquisition and interpretation
Number of subjects: 0
Study 9852937 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis
Number of subjects: 0
Study 9852937 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital identification of thrombolysis-eligible patients
Number of subjects: 0
Study 7810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 222
Study 7810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a grommet
Number of subjects: 222
Study 7810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy + grommet insertion
Number of subjects: 222
Study 7810300 — intervention group
Group type: COMPARATOR
Intervention: No surgical procedure (control)
Number of subjects: 222
Study 3935853 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (cephalosporin treatment alone: cefotaxime, cefazolin)
Number of subjects: 0
Study 3935853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two or three antibiotics
Number of subjects: 0
Study 3935853 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (general)
Number of subjects: 0
Study 3935853 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider antibiotic spectrum
Number of subjects: 0
Study 31821322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-kg/m2 BMI reduction
Number of subjects: 287394
Study 29486504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (once to twice weekly for 16 to 20 weeks, mean: 17 treatments)
Number of subjects: 73
Study 29486504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (early treatment group)
Number of subjects: 73
Study 26254755 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone hydrogel
Number of subjects: 150
Study 26254755 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid hydrogel (triamcinolone)
Number of subjects: 150
Study 26254755 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydrogel only)
Number of subjects: 150
Study 25312315 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (5 mL in two applications)
Number of subjects: 42
Study 25312315 — intervention group
Group type: COMPARATOR
Intervention: Oral paracetamol (1 gr every 8 hours for 30 days)
Number of subjects: 42
Study 22701534 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 MP commercial color LCD
Number of subjects: 5
Study 22701534 — intervention group
Group type: COMPARATOR
Intervention: 3 MP diagnostic monochrome LCD
Number of subjects: 5
Study 20393269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pressure applied to the sciatic nerve (11 to 20 kg for 2 minutes)
Number of subjects: 174
Study 20393269 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (pressure applied to parallel regions on the fronts of the thighs)
Number of subjects: 174
Study 17660520 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 1 ng ml(‐1)
Number of subjects: 33
Study 17660520 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 3 ng ml(‐1)
Number of subjects: 33
Study 17660520 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 5 ng ml(‐1)
Number of subjects: 33
Study 17660520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tet30 (30 s tetanic stimulus)
Number of subjects: 33
Study 17660520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tet5 (5 s tetanic stimulus)
Number of subjects: 33
Study 17962011 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine linkage to breast specialists in a cancer centre
Number of subjects: 473
Study 17962011 — intervention group
Group type: COMPARATOR
Intervention: In-person meetings
Number of subjects: 473
Study 14732596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glycine (0.8 g/kg/day)
Number of subjects: 17
Study 10730723 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive oral hygiene program including instruction of the carers and implementation of a recall program for professional oral hygiene care
Number of subjects: 237
Study 10730723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive oral hygiene program)
Number of subjects: 237
Study 8831317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.73% lidocaine with 10 micrograms/mL of clonidine (Group C10)
Number of subjects: 90
Study 8831317 — intervention group
Group type: COMPARATOR
Intervention: 1.73% lidocaine (Group L)
Number of subjects: 90
Study 8831317 — intervention group
Group type: COMPARATOR
Intervention: 1.73% lidocaine with 20 micrograms/mL clonidine (Group C20)
Number of subjects: 90
Study 1279289 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg three times daily)
Number of subjects: 10
Study 1279289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily) with Terbutaline
Number of subjects: 10
Study 1279289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4018101 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding (BF)
Number of subjects: 0
Study 4018101 — intervention group
Group type: COMPARATOR
Intervention: Early formula feeding (F)
Number of subjects: 0
Study 30706247 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (3.6 mg/kg q3w, 2.4 mg/kg qw)
Number of subjects: 345
Study 30706247 — intervention group
Group type: COMPARATOR
Intervention: Taxane (docetaxel/paclitaxel)
Number of subjects: 345
Study 30706247 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (2.4 mg/kg qw)
Number of subjects: 345
Study 28823926 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step GDM screening strategy
Number of subjects: 0
Study 28823926 — intervention group
Group type: COMPARATOR
Intervention: Two-step GDM screening strategy
Number of subjects: 0
Study 25732415 — intervention group
Group type: COMPARATOR
Intervention: Forward View (FV)
Number of subjects: 850